Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Amgen, Inc. Issues FY 2012 Guidance In Line With Analysts' Estimates
Amgen, Inc. announced that it continues to expect 2012 total revenue to be in the range of $16.1-$16.5 billion, and adjusted earnings per share (EPS) to be in the range of $5.90-$6.15, excluding certain expenses related to acquisitions and cost-savings initiatives, non-cash interest expense associated with our convertible notes and certain other items. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $16.3 billion and EPS of $6.07 for fiscal 2012.
Latest Developments for Amgen Inc
- Amgen Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance
- Amgen Inc Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
- FDA Halts Trials Of Amgen Inc Drug In Children, Cites Death-Reuters
- Amgen Inc Updates FY 2015 Guidance To A Range In Line With Analysts' Estimates-Conference Call
Latest Key Developments in Biotechnology
- NuSep Holdings Ltd Appoints KPMG As Company Auditor
- Rockwell Medical Inc Closes $40.3 Million Public Offering Of Common Stock
- Rockwell Medical Inc Announces PRIME Study Results At The 50th ERA-EDTA Meeting In Istanbul
- Intercept Pharmaceuticals Inc Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid Diarrhea
- Share this
- Link this
- Digg this
Follow Reuters